Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Osteoarthritis, Hip

In brief

This is a two-part, multi-center, randomized, double-blind, placebo-controlled, parallel-group study in patients with hip OA. Approximately 70 patients will be enrolled in Part I and approximately 440 patients will be enrolled in Part II of the study. In each part, patients will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either 32 mg FX006 or normal saline.

Key facts

Study ID

NCT03793010

Run by

Pacira Pharmaceuticals, Inc

People needed

70

Starts

2018-12-12

Expected to finish

2019-08-07

Last updated by the study team

2024-01-24

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions
• Patients 40 to 80 years of age, inclusive, on the day of randomization (Day 1)
• Body Mass Index (BMI) ≤ 40 kg/m2
• Symptoms associated with OA of the index hip for ≥ 3 months prior to Screening visit
• Currently meet the American College of Radiology (ACR) Criteria (clinical and radiological) for OA of the index hip
• Kellgren-Lawrence (KL) Grade 2 or 3 in the index hip as confirmed by X-ray during Screening visit (centrally read)
• Qualifying mean score on the WOMAC A and C (0-10 NRS scale)
• Agree to maintain the similar activity level throughout the study
• Willingness to abstain from use of restricted medications

You may not qualify if…

• Patients who cannot washout of prohibited medications
• Diagnosed as secondary OA in the index hip including but not limited to articular fracture, major dysplasia or congenital abnormality, osteochondritis dissecans, acromegaly, ochronosis, hemochromatosis, Wilson's disease, or primary osteochondromatosis, etc.
• Ipsilateral chronic knee pain
• Sciatica
• Atrophic osteoarthritis, femoral head necrosis and/or collapse, or subchondral bone insufficiency fracture in the index hip joint determined via central reading
• Current or history of infection in the index hip (e.g. osteomyelitis) or current skin infection at injection site
• Trauma or surgeries (e.g., arthroscopy, knee surgery) of lower limbs within 52 weeks with sequelae, etc.
• History or current evidence of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease, systemic lupus erythematosus or other autoimmune diseases
• Any planned surgeries in the lower limbs during the study period, or any other surgery during the study period that would require use of a restricted medication
• Presence of surgical hardware or other foreign body in the index hip
• Planned/anticipated surgery of the index hip or any other surgery that would require use of a restricted medication during the study period
• IA corticosteroid of any joint within 3 months of Screening visit (investigational or marketed, including FX006)
• IA treatment of index hip with any of the following agents within 6 months of Screening: any biologic agent or hyaluronic acid (investigational or marketed)
• IV or IM corticosteroids (investigational or marketed) within 3 months of Screening
• Oral corticosteroids (investigational or marketed) within 1 month of Screening
• Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening visit
• Planned or expected changes to lifestyle with regard to physical activity, physical therapy, acupuncture, transcutaneous electrical nerve stimulation (TENS), or bracing within 1 month prior to Screening and changes throughout the duration of the study
• Women of child-bearing potential (not surgically sterile or post-menopausal for at least 1 year as documented in medical history) not using a highly effective method or who are pregnant or nursing

Where it is running

• Arizona Research Center — Phoenix, Arizona, United States
• Noble Clinical Research — Tucson, Arizona, United States
• Hope Clinical Research — Canoga Park, California, United States
• TriWest Research Associates, LLC — El Cajon, California, United States
• BioSolutions Clinical Research Center — La Mesa, California, United States
• Artemis Institute for Clinical Research — San Diego, California, United States
• Mountain View Clinical Research, Inc. — Denver, Colorado, United States
• Chase Medical Research, LLC — Waterbury, Connecticut, United States
• Tampa Bay Medical Research — Clearwater, Florida, United States
• Florida Research Associates, LLC — DeLand, Florida, United States
• Advanced Research for Health Improvement — Naples, Florida, United States
• Medallion Clinical Research Institute, LLC — Naples, Florida, United States
• Oviedo Medical Research — Oviedo, Florida, United States
• Progressive Medical Research — Port Orange, Florida, United States
• Precision Clinical Research, LLC — Sunrise, Florida, United States
• National Pain Research Institute — Winter Park, Florida, United States
• Better Health Clinical Research, Inc — Newnan, Georgia, United States
• Injury Care Research, LLC — Boise, Idaho, United States
• Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
• Heartland Research Associates — Newton, Kansas, United States
• Excel Clinical Research — Las Vegas, Nevada, United States
• Drug Trials America — Hartsdale, New York, United States
• M3 Wake Research, Inc. — Raleigh, North Carolina, United States
• PMG Research of Wilmington — Wilmington, North Carolina, United States
• University Orthopedics Center — Altoona, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.